nobelbiocare.com

creos™ was launched in2014
creos™ xenoprotect

2016

creos™ xenogain
creos™ xenogain collagencreos™

The trusted regenerative partner
for you and your patients

Indication-based product overview

4

Bone grafts
creosTM xenogain				6creosTM xenogain collagen			6creosTM xenoform				82018creos™ mucogain

creosTM syntogain				10Membranes
creosTM xenoprotect				122021creos™ syntoprotect2022

creos™ syntogain
creos™ xenoform

creosTM xenofirm				14

creosTM sytoprotect mesh			

15

creos

TM

syntoprotect				16

creos

TM

syntoprotect titanium reinforced		Collagen matrix
creosTM mucogain				18Wound dressingscreosTM xenofill					2023creos™ syntostitch
creos™ xenofill
creos™ screw fixation
creos™ xenofirm2024

creos™ syntoprotect mesh

16

20

SuturescreosTM syntostitch				22Fixation systems
creosTM screw fixation 				

23Article overview				24References					32

4creos portfolio brochurecreos portfolio brochure

Indication-based
product overview

Ridge preservation

See article lists (p. 24–31) for mostcommonly used product codes

Bone grafts

MembranesWith
primary closure

Without primaryclosureHorizontal ridge
augmentation

Vertical ridge
augmentation

Peri-implant
defectSinus
augmentation

Periodontal
defects

0.5–2 g0.25–0.5 g

1–2 g

0.25 g

0.15–0.25 g

0.25–0.5 g

0.1–0.25 gcreos xenogain*

Xenogenic bone graft substitute0.25–0.5 g

0.25–0.5 g

0.25–0.5 g

creos xenogain collagencreos xenogain + 10% porcine collagen type I

0.1–0.25 g

0.1–0.5 g

0.25–0.5 g

creos xenoform*

Xenogenic bone graft substitute0.25–0.5 g

0.25–0.5 g

0.25–0.5 g

0.5–2 g0.25–0.5 g

1–2 g

0.25 gcreos syntogain*

Synthetic bone graft

0.5–1 g0.5–1 g0.5-1 g

1g

0.5 g

1g

0.5 g

creos xenoprotect

Resorbable collagen membrane

15 x 20 mm

15 x 20 mm
25 x 30 mm

25 x 30 mm
30 x 40 mm

15 x 20 mm

15 x 20 mm
25 x 30 mm

15 x 20 mm

creos xenofirm

Resorbable, firm collagen membrane

15 x 20 mm

15 x 20 mm
20 x 30 mm

20 x 30 mm
30 x 40 mm

15 x 20 mm

15 x 20 mm
20 x 30 mm

15 x 20 mm

creos syntoprotect

Non-resorbable high-density
PTFE membrane

12 x 24 mm
12 x 30 mm
25 x 30 mm

creos syntoprotect
Ti-reinforced

Non-resorbable titanium-reinforced
high-density PTFE membrane

Shapes 1 and 2

creos syntoprotect mesh

Reinforced PTFE meshcreos mucogain

Absorbable collagen matrix

creos xenofill

Absorbable wound dressing

creos syntostitch

Non-absorbable
PTFE suture–monofilamentcreos screw fixation

Self-drilling titanium
fixation screws

Soft tissue augmentation (aroundteeth or implants)

12 x 24 mm
12 x 30 mm
25 x 30 mm
Shapes depending
on defect

Shapes depending
on defect

Shapes depending
on defect

Shapes depending
on defect

Shapes depending
on defect

Shapes depending
on defect

Mesh

15 x 20 mm
25 x 30 mm

Matrices

Plug (fully intact
sockets only)

Foam, Tape(for donor site)

Wound dessings

All sizes

All sizes

All sizes

All sizes

All sizes

All types

All types

Membrane fixationscrews; Tenting screws

Sutures

Fixation system

Note See Instructions For Use for full prescribing information, including indications, contraindications, warnings and precautions.
Volumes and sizes listed are to be used as approximations and may vary depending on the defect/patient.
*Please consult article lists (p. 24–31) for conversion to volume (cc)All sizes

All sizes

4-0; 5-0

56

creos portfolio brochurecreos portfolio brochurecreos™ xenogain

Scaffold for successful
regeneration

Xenogenic bone graft used for guided boneregeneration and guided tissue regeneration

Preserved natural features of bone throughoptimized manufacturing process.2

Calcium phosphate ratio
2.0
1.679

1.680

creos™ xenogain

Human bone

1.5

Chemical composition
With a calcium phosphate ratio that reflects thecomposition in human bone and a structure withlow crystallinity, the body accepts creos xenogain
as a suitable framework for bone formation.1

1.0
0.5
0.0

Particle size
‒ Homogenous particle size1‒ Maintains space for bone regeneration4
Photographic micrograph of creos xenogain and reference productshowing the particle size distribution (magnification 20x)

Preserved nanostructure
Nanostructure preserved thanks to treatment at comparatively low temperature (600°C) and no sintering.2

Three different methods of application:

Macro and micro-structure

Vial

Bowl

Interconnected macropores allow cells to
invade bone grafts and micropores contributeto capillary liquid uptake (hydrophilicity).10,11

Syringe

1.0 mm

1.0 mmcreos™ xenogain(0.2–1.0 mm)

Reference product(0.25–1.0 mm)

Similar to human bone
‒ Chemical composition: Ca/P ratio

Solid foundation for
implant placement‒ Interconnected macropores1,2

The graft integrates with the newly formed bone,building a basis for successful implant placement.4

Easy handling‒ Homogenous particle size1‒ Hydrophilic for fast rehydration3,4

Solid foundation for dental
implant treatment“I appreciate its handling properties
and I see its high hydrophilicity as a
biological advantage in sinus graftingand peri-implant defect regeneration”

Schematic showing the defect and bone size prior to and after GBR

Histological cross section of the cellular components: new bone (NB),
bone graft (XG). Bone-to-graft-particle contact shown by dashed line.
XG+56.9%(+4 mm)XG

Dr. Werner Zechner, Austria
XG

XG

XG

‒ Osteoconductive properties2

XG‒ Long-term volume stability6435x‒ Uneventful healing7,8,4,6,9

XG

BovineInitial situation before GBR

8 months post-surgery
XG

creos™ xenogain collagen
Purified cancellous bovine bone mineral granules and 10%
porcine collagen in block form and syringe. The collagenhelps to hold creos xenogain collagen in the desired place.
Especially recommended for extraction socket management.
Block

Syringe

In a multicenter clinical study involving 46 patients,
bone increase after 8 months was 4.0 mm (+56.9 %gain) and 4.7 mm (51.0% gain) at 1 and 3 mmfrom the top of the crest, respectively.6

BovinePorcine

NB

XG

NB

100 µmNB

Histological assessment of the trephinecores showed 37.3 % of new bone, 39.1
% of graft material, and 23.6 % of soft
tissue (n = 6 cores, 3 patients).6

GBR led to robust bone regeneration during
the 8 months of healing, enabling successfulplacement of 91 implants in 43 patients, with anaverage insertion torque of 37.8 ± 5.1 Ncm.6
Scan the code formore resources.

7

creos portfolio brochurecreos portfolio brochurecreos™ xenoform
Xenogenic bone graft used for
guided bone regeneration andguided tissue regeneration

Histology: New bone formation of the graftedcreos xenoform in the human maxillary sinus cavity 3‒ Sinus graft procedures were conducted in 10 patients‒ 6 specimens used for histomorphometric analysis→ 23.5% new bone and 15.4% residual graft material
6 months after bone graft surgery→ More newly formed bone than residual graft material

Cancellous bovine bone sourced from Australia with
two application types and two granule sizes

BovineA. Residual graft material (*) circumscribed by newly formed bone.

High percentage of newly
regenerated boneMultiporosity
structure

Natural surface
topography‒ Made from 100%cancellous bone

‒ Low-temperatureprocessing technique‒ Innovative pulverizing
technique allowing
multiporous structure→ Stimulating
osteoblast activity→ Maximizing bloodvessel ingrowth

Large pore size
‒ creos xenoform has arelatively large poresize (300–400 μm)
compared to otherworld-leading
products→ Favorable for bloodvessel access anddevelopment1,2

Octacalcium
phosphatecrystals‒ In an in-vivo model to evaluate thebone healing effect of biomaterials, thepercentage of the newly formed bone withcreos xenoform and the reference productwere comparable (differences were statistically non-significant). No infections orcomplications observed after surgery.1

In the last 10+ years, creos xenoform has
been used by dental surgeons aroundthe world and in challenging clinical.
Long-term results
Stable pre-implantbone level 11 years
after tooth extraction
and immediate
implant placementwith boneaugmentation(position FDI 26)
Image courtesy of Myung Ho Lee, DDS, Republic of Korea‒ Found on the surface→ Enhancing boneregenerationand formation1

B. Ingrowth of microvessels in the newly formed bone (arrow) withlacunae in the bone lamellae.

Long-term success in clinical setting‒ Patient biopsies show 23.5±0.1%
new bone vs 15.4±0.06 residual bone
graft 6-8 months post sinus lift.3

30
New bone (%)

820

Not significant
Not significant

10

0

17.6

17.3

24.3

25.1

8 weeks

12 weeks■ creos™ xenoform■ Reference product*as shown in an animal model
Scan the code formore resources.

9

10

creos portfolio brochurecreos portfolio brochurecreos™ syntogain

Advanced manufacturing process1
creos syntogain is the latest generation of synthetic bone graft. Its manufacturing process in an
aqueous environment and at low temperature enables a bone graft with a unique composition,round granule shapes, a high surface area and a nano-/microporosity similar to natural bone.

Non-animal-based bone graft
substitute for efficient regeneration

1. Unique composition1,2,3

2. High specific surface area1,5,6‒ 80% CDHA (carbonated calcium
deficient hydroxyapatite)

Thanks to the biomimetic manufacturing process, hydroxyapatite crystals
grow on the surface of the granules. This
increases the surface area and enables thecells to attach for bone generation.16‒ 20% ß-tricalcium phosphate.
creos syntogain CDHA crystallinity resembles
that of human bone.1,2,3
The closer a material resembles human bone,
the better it is for bone formation.15

Unique composition of the material1,2,3‒ 80% of calcium-deficienthydroxyapatite (CDHA) and 20% of
BTCP (beta-tricalcium phosphate)

N2 adsorption
10.0

8.66

8.0
6.0

‒ It’s biomimetic: it mimics human bonethat is also made of CDHA1,2,3

4.0
2.0

0.52

0.0
creos™ syntogain

Microscopic surface madeof nanocrystals1,4‒ High specific surface area : helps cells
attach for new bone generation7
1,5,6‒ High microporosity, thus
enhancing bone ingrowth1,8

Current synthetics

Biomimetic

Traditional calcium phosphate(HA / B-TCP) synthetics
High-temperature manufacturing
process: passivates materials andreduces the potential of the hostto interact with it.

creos syntogain biomimetic calcium
phosphate (CDHA / B-TCP)
Low-temperature manufacturing
process: hydroxyapatite crystals
grow slowly to mimic the structure
and composition of human bone.

Traditionally sinteredcalcium phosphate

The specific surface area wasmeasured by nitrogen adsorption

Bone stability1,10Clinical outcomes17‒ The bone is stable and it maintains
the volume of the defect basedon clinical case series9,10

In one of the largest randomized clinical trials performed in dental bone regeneration with 102 patients in need ofa bone augmentation, creos syntogain showed non-inferiority with the reference deproteinized bovine bone matrix(DBBM): no statistically significant difference in the vertical and buccolingual dimensional change was observed.

And even more:
Six months post-grafting, the mean bonechange in width and height was respectively-1.78% and 1.35% for creos syntogain (n=42)
and -2.16% and 2.99% for the reference DBBM
(n=41). The differences between the twomaterials were not statistically significant.

Granules have unique round shape1,10‒ Makes it easy to apply in situ11‒ Avoids stacking effect1
High hydrophilicity12

The mean implant insertion torque was 36.2 Ncm
at sites regenerated with creos syntogain and35.1 Ncm at sites regenerated with the reference
DBBM. For creos syntogain, 71.1% of the implants
were placed with an insertion torque above
35 Ncm and 62.8% for the reference DBBM.

Vertical and horizontal change (%) at 6 months post bone grafting‒ Allows for easy hydration and granulehandling12

0.04
0.03
0.02
0.01
0
-0.01
-0.02
-0.03

Non-sintered1‒ Microporosity and osteoconductivity
are not reduced13,14

creos™
syntogain
n=45ReferenceDBBM

t-testInsertion Torque( Ncm-1 )

36.2

35.1

0.676

StDev

12.4

13.6

ISQ

70.2

70.8

StDev

12.0

9.8

3.0%
1.35%

-1.78%-2.16%

Width variation

Height variation■ creos™ syntogain■ Reference DBBM

0.770

Synthetic
Scan the code formore resources.

11

creos portfolio brochurecreos portfolio brochurecreos™ xenoprotect

High mechanical strength
In an in vitro study aiming to compare themechanical strength of commonly used native
non-chemically cross-linked and chemicallycross-linked collagen membranes4

Nobel Biocare’s highest selling
resorbable collagen membrane‒ creos xenoprotect demonstrated thehighest force at break, wet (21.2 N).
‒ creos xenoprotect had the highest suture
retention when hydrated (6.1 N).

Provides a physical barrier tocontain the bone graft material
at the defect site1,2,3,5,6,11,12,13
Prevents ingrowth of surrounding tissue for aperiod of time that is long enough to allow boneregeneration to take place.
In an animal model, after 20 weeks, the thicknessof xenoprotect decreased only slightly, whereas
the reference membrane showed a thickness lossof around 50%, confirming the higher stabilityof xenoprotect against biodegradation in vivo.3

Comparison of commercial membranes in a hydrated state30
25

Force atbreak
wet [N]

20
15
10
5

8
7
6
5
4
3
2
1
0

Easy handling

1,2

creos™ CO

JS

OF

BG

BE

ML

OP

BM

Sutureretention
wet [N]creos™ CO

JS

OF

BG

BE

ML

OP

BM

Non-cross-linked collagen membranes (NXL) – CX: creos™ xenoprotect[Nobel Biocare]; CO: Copios [Zimmer]; JS: Jason [botiss]; OF: Osseoguard
Flex [3i]; BG: Bio-Gide [Geistlich]‒ Does not stick to instruments

20 weeks

0

Representative histological images at 20
weeks implantation in a rat model.

20 weeks

12

200 µm200 µmcreos™ xenoprotect

Reference membrane

Cross-linked collagen membranes (XL) – BE: BioMend Extend [Zimmer];
ML: Mem-Lok [BioHorizons]; OP: OssixPlus [Datum Dental]; BM: BioMend[Zimmer];‒ Repositioning in-situ possible‒ Low surface expansion
when hydrated*Statistically significant‒ Both sides can face the defectFacilitates new bone formation2,3,5,6,7,8

High mechanical strength2,3,4‒ High suture retention1,4,9

New bone formation (%)‒ Highly tear-resistant

In a randomized controlled clinical trial, 24
patients were treated with creos xenoprotect
and 25 with a reference membrane. In thecreos xenoprotect group, the defect height
reduced at 6-month re-entry by 81%.

40
30

Natural collagen membrane

20‒ Non-chemically cross-linked140Facilitates bone gain

2,3,5,6,7,8‒ Beneficial clinical results7,10

15.5%

10

‒ Made from porcine collagen‒ Tested and approved
biocompatibility7,10

34.9%*“What I like is that the handling is veryeasy. The mechanical stability is very
high and when it is rehydrated it adapts
very well to the underlying bone”

creos™
xenoprotect

In a comparative in vivo study, creos xenoprotect
demonstrated significantly higher new boneformation in the central portion of the defect.
This increase in bone formation was associated withsignificantly increased expression of the growth factor
Bmp2, which has a strong role in osteogenesis.7

Dr. Bastian Wessing, Germany* As shown in an animal model (rat, subcutaneous)

ReferenceIn the reference membrane group, the defectheight reduced at 6-month re-entry by 62%.5
Schematic showing the defect height prior
to treatment and 6 months after GBR
5.1 ± 2.1 mm

4.9 ± 1.9 mm

creos™ xenoprotect

Reference

1.0 ± 1.3 mm

Porcine*Statistically significant

creos™ xenoprotect

1.7 ± 2.1 mm

Reference
Scan the code formore resources.

13

14

creos portfolio brochurecreos portfolio brochurecreos™ xenofirm

creos™ syntoprotect
meshResorbable, firm, and long-lasting
collagen membrane

Non-resorbable reinforced PTFE mesh for thestabilization and support of bone grafts inhorizontal and vertical ridge augmentations
Adaptability of amembrane withporosity of a mesh
Maintains space essential
for horizontal and verticalridge augmentations, butwith the benefits of easiertrimming and adaptation.

Unique macroporous
designDirect contact between bone
graft and periosteum allows
naturally occurring revascularization and infiltrationof cells into the bone graft.

Handling options

Optimized flexibility

15 shapes adapted to treat
different indications.

‒ Stiff enough for easy placement,
yet easily drapes over ridge

Long predictable
resorption time

Synthetic‒ Resorption time 26–30 weeks

Vertical bone augmentation usinga reinforced PTFE mesh1

High tensile strength

A study published by Urban et al. that included 57 patients(65 defects) found that the mean absolute bone gain after
vertical bone augmentation with a reinforced PTFE mesh
was 5.2 ± 2.4 mm, with a relative gain of 96.5 ± 13.9%.
Overall, 89.2% of cases showed complete regeneration.

‒ Suture or tack the membranein place without tearing

5.5 ± 2.6 mm

96.5% ± 13.9%

5.2 ± 2.4 mm

Manufactured from highly purified
Type 1 bovine Achilles tendon
Reconsituted fiber construction allows
tissue integration while preventing
direct passage of epithelial cells.

Baseline vertical deficiency
5.5 ± 2.6 mm

Vertical bone augmentation usinga reinforced PTFE mesh

Mean absolute bone gain
5.2 ± 2.4 mm“The creos PTFE mesh allows thevascularization you get from amesh, but with the softness of amembrane that remains kind tosoft tissues. With the mesh, andthe bone quality I see at sevenmonths, I am able to shorten time
to implants by about two months.”
Istvan Urban DMD, MD, PhD

BovineScan the code formore resources.

15

16

creos portfolio brochurecreos portfolio brochurecreos™ syntoprotect

Unique properties of dense PTFE membranes
Dense PTFE

Expanded PTFE

Non-resorbable dense PTFE membrane
for extraction socket management, ridge
augmentations, and grafting of large defects

Preserves soft tissue architectureand keratinized mucosa

20 µm

SEM image courtesy of Schüpbach Ltd, Switzerland.

SEM image courtesy of Schüpbach Ltd, Switzerland.

Designed to aid in membrane stabilization

syntoprotect
PTFE membrane
Purposely leave themembrane exposed

20 µm

100% dense (non-expanded) PTFE
Impervious to bacteria – pore size
less than 0.3 µm

Non-resorbable

Soft tissue attaches, but doesn’t
grow through the membrane

Will not resorb prematurely – youdictate healing time

Exposed membrane allows for non-surgical removal; no anesthesia required

Dense PTFE was designed towithstand exposure in the oral
environment, which represents an
improvement to earlier versionsof expanded PTFE in applications
such as ridge preservation where
deliberate membrane exposure
offers several advantages.

200 µmAlthough PTFE isinherently a non-stickmaterial, cells attach
to the outside of thedense PTFE membranes.
Cellular adhesion isimportant to create aseal around the edgesof exposed dense PTFE
membranes or to support
primary closure in larger
graft applications.

Hexagonal surface
dimples provide a
textured surface that
increases the area
available for cellular
attachment without
increasing porosity.
The textured surface isdesigned to help stabilize
the membrane andthe soft tissue flap.

SEM image courtesy of Schüpbach Ltd, Switzerland.

Synthetic

Clinical evidence
Efficacy

syntoprotect
Ti-reinforced
PTFE membrane

Bone loss 1-year post-extraction1

Soft tissue regeneration 90
days post-extraction2

Vertical ridge augmentation around implants3

1.5

100%

6

N=12

5

5.49 mm

1.0

0.5

0

Delicate, lightweight framework

Handling options

Easy to trim and compliant withthe overlying soft tissues

Broad portfolio with 15 shapes
in two thicknesses

Less is more

Traditional frame design

Less titanium bulk allows for greater
versatility in shaping and placement,
providing additional stability in large,
non-spacemaking osseous defects

Incorporating delicate and strategically-placed titanium “struts”
with more than 25 years of clinicalhistory and successful use in GBR

N=15

4

59.68%

3

N=100.25 mm
Verticalbone loss

N=150.30 mmHorizontalbone loss

Vertical bone loss measured at crest. Horizontal
measured from stent to buccal plate.

18.25%
0%syntoprotect PTFE No membrane
membrane

Measured as reduction of the occlusal distance
between buccal and lingual gingival margins.

N=11
4.91 mm2
1
0syntoprotect
Ti-reinforced
PTFE membrane

Expanded PTFE

Mean vertical bone regeneration.

Predictability
In two separate studies treating a total of 696 extraction
sites using dense PTFE membranes in an exposed
technique, there were no reported infections.4,5Scan the code formore resources.

17

18

creos portfolio brochurecreos portfolio brochurecreos™ mucogain

Use straight out of the box

creos™ mucogain

creos mucogain is intended to be used forsoft tissue augmentation indications in
the oral cavity around teeth or implants:

Collagen matrix designed topromote soft tissue regeneration‒ Guided tissue regeneration(GTR) procedures in recession
defects for root coverage.
‒ Localized gingival augmentation to increase keratinized tissue
around teeth and implants.

Substitutes the need for asecond surgical site1,2,3

Unique oriented porous structure
Initialvolume1. Matrix structureInterconnecting porous structure produced by apatented process.4,5,6

Patented manufacturing method

Compressed

Back to initial
volume2. Mechanical properties
After hydration and compression in 49 cycles in vitro,
the graft regains its initial volume.4‒ Open interconnecting porous structure.

3. Biological outcome
Designed to promote soft tissue regeneration
through the migration of cells and blood vessels into
the matrix.4,6‒ Designed to promote soft tissue regeneration through the migration of cells
and blood vessels into the matrix.4,5,6

Clinically effective7,8,9,10

Variety of choices

Clinically effective for soft tissue regeneration in combination with immediate implant
placement and bone grafting procedure.7,8‒ A choice of different sizes and thicknesses.

Excellent handling
Clinical case

‒ Easy to use7
‒ High suture retention and stress resistance‒ Memory effect after hydrationand cycling loading in vitro4‒ Trim to precisely fit surgical site7

A retrospective analysis including 45 patientswith a follow-up of up to 4.5 years (mean of 1.8± 1.3 years) demonstrated that creos mucogain
promotes soft tissue health and maintains
adequate soft tissue thickness when usedsimultaneously with implant placement.9

7“It felt like an autogenous tissue
graft and the mechanicalstability is amazing”

Buccal view prior to surgery (left) and 8 months after surgery (right) on#22, #24, #25, #26 after treatment with creos mucogain.

Dr. Miguel González Menéndez, Spain

Clinically effective‒ Shown to promote soft tissue healthand maintain adequate soft tissue
thickness in a clinical study.23,24,25,26
PorcineCirillo F. (March 2020). Periodontal plastic surgery: gingival recession coverage with a xenogenic collagen matrix.
The Foundation for Oral Rehabilitation (FOR.org): https://bit.ly/2TkLsgu (Images reprinted with permission of
the author and FOR.)
Scan the code formore resources.

19

20

creos portfolio brochurecreos portfolio brochurecreos™ xenofill

Absorbable wound dressings to protect
wound beds and aid in wound healing

Available in 3 shapes and sizes
Made from purified collagen
derived from bovine tissue
Essentially resorbs in 30 days

Tape
2.5 cm x 7.5 cm x 1 mm (thick)

Applications:‒ Surgical wounds

Plug
1 cm x 2 cm

‒ Periodontal surgical wounds‒ Extraction sites‒ Dental sores‒ Oral ulcers (non-infected or viral)‒ Suture sites‒ Burns

Foam
2 cm x 4 cm x 3 mm (thick)‒ Traumatic wounds

BovineScan the code formore resources.

21

creos portfolio brochurecreos portfolio brochurecreos™ syntostitch

creos™ screw fixation

Non-absorbable monofilament
PTFE sutures

Instruments and screws for fastand easy placement of membrane,bone block, and tenting screws

Smooth monofilament rod

Advantages of the 300 series
stainless steel needles:
creosTM syntostitch

PTFE competitor

350x magnification

350x magnification‒ Gold standard material
for suture needles‒ Increased needle strengthand needle sharpness‒ Less force to penetrate

100% medical-grade PTFE Biologically inert

One kit for three types of screws

Monofilament Does not wick bacteria

Resistance to bending
25

Soft (not stiff) Comfortable for patients
Little to no package memory Excellent handling, knots securely

49.5%
increase

Bending force

22‒ Instruments designed to work universallywith all creos screw fixation screw types

Self-drilling screws
400 Series
steel needles*

300 Series
steel needles*common in dentistry‒ The self-drilling design of the membrane
fixation and tenting screws allows penetration
through cortical bone without the use of amallet or the need for drilling pilot holes

Stable and secure fixation
Needle shapes
TP 1/2 circle
Round-bodied

Thread diameters

Recommended knot1
Single throw reverse

2-0

3-0

4-0

5-0
Single throw forward
Double throw forward

RC 3/8 circle
Precision reverse
cutting

Secure membranes
and meshTenting screws0

Non-resorbable Keeps the surgical site reliably closed‒ Variety of membrane fixation,bone fixation, and tenting screws

Membranefixation screws‒ Easy pick-up, solid stability of the screw duringtransfer to the surgical site, and easy placement
make membrane fixation fast and easy

Maintain space under
membranes in horizontal
and vertical augmentation
procedures

Bone fixation screws

Stabilize, fixate, and support
bone block grafts

Contra-angle blade(optional)

Designed for posterior andlingual screw placement,
it attaches to latch typemotorized hand pieces
and works universallywith all creos screws

23

24

creos portfolio brochurecreos portfolio brochure

Products
creos™ xenogain

creos™ xenoform

Xenogenic bone graft substitute

Xenogenic bone graft substitute

Weight0.25 g0.5 g

1.00 g2.00 g15 °C

Granule size

VolumeVial

Bowl

Syringe

WeightSmall (0.2–1.0 mm)

0.36 cc

N1110

N1110-B

N1210

0.25 gLarge (1.0–2.0 mm)

0.54 cc

N1111

N1111-B

N1211

0.5 g

Granule size

0.2–1.0 mm

VolumeVial (Granules)

Syringe

0.5 ccCHY25-0210

CHYS25-0210

1.1 ccCHY05-0210

CHYS05-0210

2.1 cc

CHY10-0210

Small (0.2–1.0 mm)

0.82 cc

N1120

N1120-B

N1220

1.0 g

Large (1.0–2.0 mm)

1.27 cc

N1121

N1121-B

N1221

2.0 g

4.1 ccCHY20-0210

Small (0.2–1.0 mm)

1.71 cc

N1130

N1130-B

0.25 g

0.6 ccCHY25-0512

CHYS25-0512

Large (1.0–2.0 mm)

2.69 cc

N1131

N1131-B

0.5 g

1.2 ccCHY05-0512

CHYS05-0512

2.3 cc

CHY10-0512

4.5 ccCHY20-0512

Small (0.2–1.0 mm)

3.64 cc

N1140

N1140-B

1.0 g

Large (1.0–2.0 mm)

5.74 cc

N1141

N1141-B

2.0 g

25 °C

0.5–1.2 mm

15 °C

Made in
Korea

25 °C

Made in Korea
from Australian bonecreos™ xenogain collagencreos™ syntogain

creos™ xenogain + 10% porcine collagen type I

Synthetic bone graft

WeightBlock size

Article no.

Weight0.1 g

6 × 6 × 6 mm

N1320

WeightSyringe size

Article no.

0.25 g7 × 8 × 9 mm

N1330

0.25 g

4.6 × 40 mm

0.5 g

9 × 10 × 11 mm

N1340

0.5 g

5.6 × 45 mm

2 °C

30 °C

Granule size

Volume

Vial

0.5 g

Small (0.2–1.0 mm)

0.50 cc

S1110

N1410

1.0 g

Small (0.2–1.0 mm)

1.00 cc

S1120

N1420

0.5 g

Large (1.0–2.0 mm)

0.50 cc

S1111

1.0 g

Large (1.0–2.0 mm)

1.00 cc

S1121

Made in
Korea

10 °C

Symbol glossary
Temperature limit
Upper limit of temperature

Most commonly sold articles

30 °C

Made in
Spain

25

26

creos portfolio brochurecreos portfolio brochurecreos™ xenoprotect

creos™ syntoprotect Ti-reinforced PTFE membrane

Nobel Biocare’s highest selling
resorbable collagen membrane

Non-resorbable, titanium reinforced, high-density PTFE membrane

Size

Shape

Article no.

15 × 20 mm

E1520

25 × 30 mm

E2530

30 × 40 mm

E3040

25 °C

No. 1

Resorbable, firm, collagen membrane
Size

Units/box

Article no.

15 × 20 mm

2

CLMCM1520

20 × 30 mm

2

CLMCM2030

30 × 40 mm

2

CLMCM3040

30 °C

Made inUSA

creos™ syntoprotect PTFE membrane
Non-resorbable, high-density PTFE membrane
Shape

Picture

Small

Size
12 × 24 mm

Medium12 × 30 mm

Large

25 × 30 mm

15 °C

Size
12 × 24 mm

No. 1,
30 mm

12 × 30 mm

No. 2

14 × 24 mm

No. 3

17 × 25 mm

Made inGermany

creos™ xenofirm

15 °C

Picture30 °C

Thickness

Article no.

Units/box

200 μm

N161224-1

1200 μm

N161224-1010200 μm

N161230-1010200 μm

N162530-1

1200 μm

N162530-4

Description

Designed specificallyfor extraction
site grafting andaugmentation
procedures where
exposure to the oralcavity is common

No. 3,
30 mm

17 × 30 mm

No. 4

20 × 25 mm

No. 5

36 × 25 mm

No. 6

25 × 30 mm

No. 7

30 × 41 mm

No. 8

30 × 40 mm

No. 9

30 × 40 mm

No. 1024 × 38 mm

No. 1138 × 38 mm

No. 1238 × 38 mm

No. 1340 × 50 mm

4Made in
USA

15 °C

30 °C

Made inUSA

Thickness

1 unit per box

2 units per box

150 μm

N1615TI-01-1

N1615TI-01-2

250 μm

N1625TI-01-1

N1625TI-01-2

150 μmn/a

n/a

250 μm

N1625TI-01-30-1

N1625TI-01-30-2

150 μm

N1615TI-02-1

N1615TI-02-2

250 μm

N1625TI-02-1

N1625TI-02-2

150 μm

N1615TI-03-1

N1615TI-03-2

250 μm

N1625TI-03-1

N1625TI-03-2

150 μm

N1615TI-03L-1

N1615TI-03L-2

250 μm

N1625TI-03L-1

N1625TI-03L-2

150 μm

N1615TI-04-1

N1615TI-04-2

250 μm

N1625TI-04-1

N1625TI-04-2

150 μm

N1615TI-05-1

N1615TI-05-2

250 μm

N1625TI-05-1

N1625TI-05-2

150 μm

N1615TI-06-1

N1615TI-06-2

250 μm

N1625TI-06-1

N1625TI-06-2

150 μm

N1615TI-07-1

N1615TI-07-2

250 μm

N1625TI-07-1

N1625TI-07-2

150 μm

N1615TI-08-1

N1615TI-08-2

250 μm

N1625TI-08-1

N1625TI-08-2

150 μm

N1615TI-09-1

N1615TI-09-2

250 μm

N1625TI-09-1

N1625TI-09-2

150 μm

N1615TI-10-1

N1615TI-10-2

250 μm

N1625TI-10-1

N1625TI-10-2

150 μm

N1615TI-11-1

N1615TI-11-2

250 μm

N1625TI-11-1

N1625TI-11-2

150 μm

N1615TI-12-1

N1615TI-12-2

250 μm

N1625TI-12-1

N1625TI-12-2

150 μm

N1615TI-13-1

N1615TI-13-2

250 μm

N1625TI-13-1

N1625TI-13-2

Description

Designed for narrow singletooth extraction sites, especiallywhere one bony wall is missing

Designed for single-tooth
extraction sites, especially where
one or more bony walls are missing

Designed for large buccal defects

Designed for large extraction sites
and limited ridge augmentation
Designed for large extraction sites
and limited ridge augmentationin the anterior maxilla
Designed for large bony defects,
including ridge augmentation
Designed for large bony defects,
including ridge augmentationin the anterior maxilla
Designed for very large
bony defects, including
ridge augmentation
Designed for very large
bony defects, including
ridge augmentation
Designed for large extraction sites,
including ridge augmentation

Designed for large bony defects,
including ridge augmentation
Designed for large bony defects,
including distal extensionof the posterior ridge
Designed for the largest
bony defects, including
ridge augmentation

27

28

creos portfolio brochurecreos portfolio brochurecreos™ syntoprotect meshcreos™ xenofill

Non-resorbable mesh

Absorbable wound dressing

Shape

PictureSize

Thickness

1 unit per box

Description

No. 3

17 × 25 mm

200 μm301871

No. 3,
30 mm

17 × 30 mm

200 μm301892

No. 4

20 × 25 mm

200 μm301872

Designed for large extraction sites
and limited ridge augmentation

No. 5

36 × 25 mm

200 μm301873

Designed for large extraction sites
and limited ridge augmentationin the anterior maxilla

Designed for large buccal defects

No. 6

25 × 30 mm

200 μm301874

Designed for large bony defects,
including ridge augmentation

No. 7

30 × 41 mm

200 μm301875

Designed for large bony defects,
including ridge augmentationin the anterior maxilla

No. 8

30 × 40 mm

200 μm301876

Designed for very large bony defects,
including ridge augmentation

No. 9

30 × 40 mm

200 μm301877

No. 9M

30 × 40 mm

200 μm301878

No. 1024 × 38 mm

200 μm301879No. 10M

24 × 38 mm

200 μm301880Designed for very large bony defects,
including ridge augmentation

Designed for large extraction sites,
including ridge augmentation

Size

Size

Units/box

Article no.

Plug

1 × 2 cm10

CLMBDDWDP1020

Foam

2 × 4 cm10

CLMBDDWDF2040

Tape

2.5 × 7.5 cm

10

CLMBDDWDT2575

10 °C

30 °C

creos™ syntostitch
Non-absorbable PTFE suture – monofilament
Needle shape
TP 1/2 circle
Round-bodied

No. 1138 × 38 mm

200 μm301881
Designed for large bony defects,
including ridge augmentation

No. 11M

38 × 38 mm

No. 1238 × 38 mm

No. 1340 × 50 mm

15 °C

30 °C

200 μm200 μm200 μmBlock size

Article no.

15 × 20 mm

3 mm

MU1520325 × 30 mm

3 mm

MU2530315 × 20 mm

5 mm

MU15205

25 × 30 mm

5 mm

MU25305

Made inGermany

Needle
size

4-0

13 mm

3018153018162-0

19 mm

30180530180616 mm

30180730180819 mm

301809301810301883

Designed for large bony defects, including
distal extension of the posterior ridge

301886

Designed for the largest bony defects,
including ridge augmentation

3-0

RC 3/8 circle
Precision
reverse cutting
4-0

5-0

Absorbable collagen matrix

25 °C

USP

301882

Made inUSA

creos™ mucogain
Size

Made in
USA

15 °C

30 °C

Made inUSA

Needlecolor

Suture length 45 cm Suture length 70 cm
12 units per box
12 units per box

16 mm

black

301811301812

19 mm

black

30181330181413 mm

30181730181816 mm

30181930182013 mm

30182130182216 mm301823301824

TP 1/2 circle
Round-bodied

RC 3/8 circle
Precision reverse cutting

2-0

3-0

4-0

5-0

29

30

creos portfolio brochurecreos portfolio brochurecreos™ screw fixation
Titanium screws for membrane/bone fixation and tenting

Membrane fixation kit Article 301779
Products included

Size

Stabilization kit
Self-drilling membrane
fixation screw

QTY
1

1.5 × 3 mm

20

Membrane fixationscrews

Ø 2.5

Size

5 units
per box

1.5 × 3 mm

301780

1.5 × 5 mm

301781LØ 1.5

Made in
USA

Made in USA

Stabilization kit includes‒ Storage tray with screw organizer dialTenting screws‒ Stainless steel driver handle‒ 76 mm cruciform driver blade

Tenting kit Article 301782‒ 56 mm cruciform driver blade

Products included

Size

Size

Special1 unit per box

5 units per box

3017833017843017853017863017873017881

1.5 × 3 mm polished neck

1.5 × 3 mm

4

1.5 × 4 mm polished neck

1.5 × 4 mm

41.5 × 5 mm polished neck

1.5 × 5 mm

4

1.5 × 8 mm

fully threaded

301789n/a

1.5 × 10 mm

fully threaded

301790n/aStabilization kit

Self-drilling tenting screw

QTY+4 mm threaded
portionPolished
neck

Fully
threaded

Ø 3.5

Ø 3.5

L
L
4

Ø 1.5

Ø 1.5

Made inUSA

Contra angle driver blade
Description
24 mm

Article no.
301802

Products included

1 unit per box

Cruciform driver blade, 76 mm

301800

Cruciform driver blade, 56 mm

301801

Stainless steel driver handle

301803

Autoclavable storage tray

301804Size

Stabilization kit

Self-tapping bone
fixation screw

Individual components
Description

Ø 2.5

Bone fixation kit Article 301791
QTY
1
1.5 × 8 mm

2

1.5 × 10 mm

4

1.5 × 12 mm

4

1.5 × 14 mm

2

Bone fixation screwsSize

1 unit per box

5 units per box

1.5 × 8 mm

301792301793

1.5 × 10 mm

301794301795

1.5 × 12 mm

301796301797

1.5 × 14 mm

301798301799L

All measurements
in millimeters.

Made inUSAØ 1.5

Connect toNobel Biocare
Online store

31

32

creos portfolio brochurecreos portfolio brochure

References
creos™ xenogain

creos™ xenoform

1. Nobel Biocare, data on file.

1. Suzuki O, Shiwaku Y, Hamai R. Octacalcium
phosphate bone substitute materials: Comparison
between properties of biomaterials and other calcium
phosphate materials. Dent Mater J. 2020;39(2):187199. doi:10.4012/dmj.2020-00 Read on Pubmed

2. Rhee S-H, Park HN, Seol Y-J et al. Effect of heattreatment temperature on the osteoconductivity of the apatite derived from bovine bone. 2006
Key Engineering Materials 309-311:41-44 Read
3. Arrighi I, Wessing B, Rieben A, et al. Resorbablecollagen membranes expansion in vitro. J Dent
Res 2014;93 (Spec Iss B):631 Read on Pubmed
4. Park JB, et al. Maxillary sinus floor augmentation using deproteinized bovine bone-derived bone
graft material (OCS-B). Clinical and histologic
findings in humans. The Journal of the Korean Dental
Association. 2007;45(8):491–99 Read on Pubmed
5. Shin S-Y, et al. Long-term results of new deproteinized bovine bone material in a maxillarysinus graft procedure. J Periodontal ImplantSci. 2014;44;259-64. Read on Pubmed
6. Aleksic Z, Milikovic I, Lazic Z, et al. A multicenter
clinical investigation demonstrates bone regeneration in severe horizontal defects in the posterior
mandible using creos™ xenoprotect: Interim results.
J Clin Periodontol 2018;45(S19):306 Read
7. Park HN, Han, SH, Kim KW, et al. A study on
the safety and efficacy of bovine bone-derived
bone graft material (OCS-B). J Korean Acad
Periodontol. 2005 Jun;35(2):335 – 43 Read
8. Kim Y-T, et.al. Periodontal Repair on
Intrabony Defects treated with Anorganic
Bovine-derived Xenograft.J Korean Acad
Periodontol. 2007;37(3):489 – 96

2. Anil A, Sadasivan A, Koshi E. Physicochemical
Characterization of Five Different Bone Graft
Substitutes Used in Periodontal Regeneration:
An In Vitro Study. J Int Soc Prev Community
Dent. 2020;10(5):634-642. Published 2020 Sep
28. doi:10.4103/jispcd.JISPCD_263_20 Read
3. JH. Lee, JH Kim, JHong Jeon, Bone Regenerationof Macropore Octacalcium Phosphate–Coated
Deproteinized Bovine Bone Materials in Sinus
Augmentation: A Prospective Pilot Study, Implant
Dentistry, 2015;24(3):275-280 Read on Pubmed

creos™ syntogain
1. Hoornaert A, Maazouz Y, Pastorino D, et al. Vertical
Bone Regeneration with Synthetic Biomimetic Calcium
Phosphate onto the Calvaria of Rats. Tissue Eng
Part C Methods. 2019 Jan;25(1):1-11. doi: 10.1089/ten.
TEC.2018.0260. PMID: 30501579. Read on Pubmed
2. Barba A, Diez-Escudero A, Espanol M, et al.
Impact of biomimicry in the design of osteoinductive bone substitutes: nanoscale matters.
ACS Appl. Mater. Interfaces 2019. DOI:10.1021/
acsami.8b20749. Read on Pubmed
3. Data on file: Mimetis XRD analysis
report using the RIR quantification method.
Medical device composition certificate.

9. Fernandez de Grado G, Keller L, Idoux-Gillet Y
et al. Bone substitutes: a review of their characteristics, clinical use, and perspectives for largebone defects management. Journal of Tissue
Engineering Volume 9: 1–18, 2018 Read on Pubmed

4. Barba A, Diez-Escudero A, Maazouz Y, et al.
Osteoinduction by foamed and 3D-printed calcium
phosphate scaffolds: effect of nanostructure andpore architecture. ACS Appl. Mater. Interfaces 2017.
DOI:10.1021/acsami.7b14175. Read on Pubmed

10. Zhang K, Fan Y, Dunne N et al. Effect of
microporosity on scaffolds for bone tissue
engineering. Regenerative Biomaterials,
2018, 115–124 Read on Pubmed

5. Sadowska JM, Guillem-Marti J, Montufar EB,
Espanol M, Ginebra MP. * Biomimetic Versus
Sintered Calcium Phosphates: The In Vitro
Behavior of Osteoblasts and Mesenchymal StemCells. Tissue Eng Part A. 2017 Dec;23(2324):12971309. doi: 10.1089/ten.TEA.2016.0406. Epub 2017
Feb 21. PMID: 28107811. Read on Pubmed
6. Data on file: Milestone 2 study (page 18)

7. Konka J, Espanol M, Bosch BM, de Oliveira E,
Ginebra MP. Maturation of biomimetic hydroxyapatite in physiological fluids: a physicochemicaland proteomic study. Mater Today Bio. 2021 Sep
15;12:100137. doi: 10.1016/j.mtbio.2021.100137. PMID:
34632362; PMCID: PMC8487082. Read on Pubmed
8. Hannink G, Arts C. Bioresorbability, porosityand mechanical strength of bone substitutes:
What is optimal for bone regeneration?
Injury, Volume 42, Supplement 2, 2011, Pages
S22-S25, ISSN 0020-1383. Read on Pubmed
9. Data on file: Clinical cases from 2022.
10. Raymond Y, Pastorino D, Ginebreda I, etal. Computed tomography and histologicalevaluation of xenogenic and biomimetic bone
grafts in three-wall alveolar defects in minipigs.
Clin Oral Investig. 2021 Dec;25(12):6695-6706.
doi: 10.1007/s00784-021-03956-y. Epub 2021
May 1. PMID: 33931811. Read on Pubmed
11. Data on file: Granules handling Voice ofCustomer from 2017-2018 + GKEM Handling
Questionnaires Results from 2022.
12. Data on file: Milestone 2 report (chapter 2.5.1)
13. Henkel KO, Gerber T, Lenz S, Gundlach
KK, Bienengräber V. Macroscopical, histological, and morphometric studies of porous bonereplacement materials in minipigs 8 months
after implantation. Oral Surg Oral Med Oral
Pathol Oral Radiol Endod. 2006 Nov;102(5):60613. doi: 10.1016/j. tripleo.2005.10.034. Epub 2006
May 19. PMID: 17052636. Read on Pubmed
14. Weibrich G, Trettin R, Gnoth SH, et al. Bestimmung
der Größe der spezifischen Oberfläche vonKnochenersatzmaterialien mittels Gasadsorption.
(Alternate title: Analysis of the size of the specificsurface area of one regeneration materials
by gas adsorption). Mund Kiefer GesichtsChir(2000) 4:148-152 Springer-Verlag 2000. Read
15. Rufino Senra M, de Fátima Vieira Marques M.
Synthetic Polymeric Materials for Bone Replacement. J.
Compos. Sci. 2020,4, 191;doi:10.3390/jcs4040191. Read
16. Ginebra MP, Espanol M, Maazouz Y, Bergez
V, Pastorino D. Bioceramics and bone healing.
EFORT Open Rev 2018;3 DOI: 10.1302/20585241.3.170056. Read on Pubmed
17. Ginebra Cairó I., Roig Cayón M., VelascoOrtega E. et al., Biomimetic synthetic bone graftin alveolar ridge preservation: 1-year RCT results,
Abstract N°EAO-647 EAO Geneva 2022.

creos™ xenoprotect
1. Aleksic Z. A multicenter clinical investigation demonstrates bone regeneration in severe
horizontal defects in the posterior mandibleusing creos xenoprotect: Interim results.
Conference: Europerio 9, July 2018. Read
2. Wessing B, Emmerich M, Bozkurt A. Horizontal
ridge augmentation with a novel resorbablecollagen membrane: a retrospective analysis of 36
consecutive patients. Int J Periodontics Restorative
Dent 2016;36(2):179–187. Read on Pubmed
3. Bozkurt A, Apel C, Sellhaus B, et al. Differences indegradation behavior of two non-cross-linked collagenbarrier membranes: an in vitro and in vivo study. Clin
Oral Impl Res; 2014; 25(12):1403-1411 Read on Pubmed
4. Gasser A, Wessing B, Eummelen L, et al. Mechanicalstability of collagen membranes: an in vitro study.
J Dent Res 2016;95(Spec Iss A): 1683 Read
5. Wessing B, Urban I, Montero E, et al. A
multicenter randomized controlled clinical trial
using a new resorbable non-cross- linked collagenmembrane for guided bone regeneration at
dehisced single implant sites: interim results ofa bone augmentation procedure. Clin Oral Impl
Res; 2017;28(11):e218–e226. Read on Pubmed
6. Sanz-Sanchez I, Wessing B, Polizzi G, etal. Randomized clinical trial comparing two
resorbable collagen membranes demonstrates good bone formation and soft tissue
healing with GBR at single implant sites
with dehiscence defects. J Clin Periodontol
2018;45(S19):19–20 [oral presentation]. Read
7. Omar O, Dahlin A, Gasser A, et al. Tissue
dynamics and regenerative outcome in two
resorbable noncross- linked collagen membranes
for guided bone regeneration: A preclinicalmolecular and histological study in vivo. Clin Oral
Impl Res; 2018;29(1):7–19 Read on Pubmed
8. Aleksic Z, Milikovic I, Lazic Z, et al. A multicenter
clinical investigation demonstrates bone regeneration in severe horizontal defects in the posterior
mandible using creos™ xenoprotect: Interim results.
J Clin Periodontol 2018;45(S19):306 Read
9. Raz P, Brosh T, Ronen G, Tal H. Tensile Propertiesof Three Selected Collagen Membranes.
Biomed Res Int. 2019 Dec 5;2019:5163603.
doi: 10.1155/2019/5163603. PMID: 31886222;
PMCID: PMC6915138. Read on Pubmed

33

34

creos portfolio brochure

10. Jäger M, Degistirici O, Knipper A, Fischer J,
Sager M, Krauspe R. Bone healing and migrationof cord blood-derived stem cells into a critical size
femoral defect after xenotransplantation. J Bone
Miner Res. 2007;22(8): 1224-33. Read on Pubmed
11. Redemagni M, Mascetti T, Garlini G. PostExtractive Immediate Implant Placement
and Immediate Provisionalization at Sites
Requiring Buccal Bone Regeneration:. EC
Dental Science. 2019(18.6): 1207-16. Read
12. Cadenas-Vacas G, Martínez-Rodríguez N, BaronaDorado C, Sánchez-Labrador L, Cortés-Bretón
Brinkmann J, Meniz-García C, et al. Calcium Phosphate
Modified with Silicon vs. Bovine Hydroxyapatite for
Alveolar Ridge Preservation: Densitometric Evaluation,
Morphological Changes and Histomorphometric Study.
Materials (Basel) [Internet]. 2021;14(4): 940. Read
13. Bruyckere T de, Cosyn J, Younes F, Hellyn J, Bekx
J, Cleymaet R, et al. A randomized controlled study
comparing guided bone regeneration with connective
tissue graft to reestablish buccal convexity: One-year
aesthetic and patient-reported outcomes. Clin Oral
Implants Res. 2020;31(6): 507-16. Read on Pubmed
14. J. Jiménez Garcia, S. Berghezan, J.M.M.
Caramês, M.M. Dard, D.N.S. Marques, Effectof cross-linked vs non-cross-linked collagenmembranes on bone: A systematic review, J
Periodont Res. 2017;1–10. Read on Pubmed
Bruyckere T de, Eeckhout C, Eghbali A, Younes F,
Vandekerckhove P, Cleymaet R, et al. A randomized
controlled study comparing guided bone regeneration with connective tissue graft to re-establish
convexity at the buccal aspect of single implants:
A one-year CBCT analysis. J Clin Periodontol.
2018;45(11): 1375-87. Read on Pubmed
González Regueiro I, Martínez Rodriguez N, Barona
Dorado C, Sanz-Sánchez I, Montero E, Ata-Ali J,
et al. Surgical approach combining implantoplasty
and reconstructive therapy with locally delivered
antibiotic in the treatment of peri-implantitis: A
prospective clinical case series. Clin Implant Dent
Relat Res. 2021;23(6): 864-73. Read on Pubmed

creos™ syntoprotect
1. Fotek PD, Neiva RF, Wang HL. Comparisonof dermal
matrix and polytetrafluoroethylenemembrane forsocket bone augmentation: a clinicaland histologic
study. J Periodontol 2009;80:776-785. Read on Pubmed

creos portfolio brochure

2. Barboza EP, Francisco BS, Ferreira VF. Soft tissue
enhancement using non-expanded PTFE membranes
without primary closure [abstract]. Presented atthe 2008 Research Forum Poster Session. Annual
Meeting of the American Academy of Periodontology(AAP) in Seattle, WA, September 6-9, 2008.

4. Damink L.O., Heschel I, Leemhuis H. et al Gasser A,
Wessing B, Eummelen L, et al. Soft tissue volume augmentation in the oral cavity with a collagen-based 3D
matrix with orientated open pore structure. Current
Directions in Biomedical Engineering 2018; 4(1): 237– 241 References 1-10 11-20 Read on Researchgate

3. Ronda M, Rebaudi A, Torelli L, Stacchi C. Expanded
vs. dense polytetrafluoroethylene membranes invertical ridge augmentation around dental implants:
a prospective randomized controlled clinical trial. Clin
Oral Impl Res; 2014 Jul;25(7):859-66. Read on Pubmed

5. Heschel I, et al. 2002. Method for producingporous structures. US patent 6,447,701 B1.

4. Barboza EP, Stutz B, Ferreira VF, Carvalho W.
Guided bone regeneration using nonexpanded polytetrafluoroethylene membranes in preparation
for dental implant placements - a report of 420
cases. Implant Dent. 2010;19:2-7. Read on Pubmed
5. Hoffman O, Bartee BK, Beaumont C, Kasaj A, Deli
G, Zafiropoulos GG. Alveolar bone preservation in
extraction sockets using non-resorbable dense PTFE
membranes: A retrospective non-randomized study.
J Periodontol 2008;79:1355-1369. Read on Pubmed

creos™ syntoprotect mesh
1. Urban IA, Saleh MHA, Ravidà A, Forster A, Wang
HL, Barath Z. Vertical bone augmentation utilizing
a titanium-reinforced PTFE mesh: A multi-variate
analysis of influencing factors. Clin Oral Implants
Res. 2021 Jul;32(7):828-839. Read on Europe PMC.
2. Bettini S, Rengo C, Fiorino A, Cucchi A. Vertical
Ridge Augmentation Using Reinforced PTFE Mesh
Versus Customized Titanium Mesh. Preliminary Results
Of A Randomized Clinical Trial. Poster presented
at the 2020 IAO in Milan Italy. Access the study.

creos™ mucogain
1. Aguirre-Zorzano LA, García-De La Fuente AM,
Estefanía-Fresco R, et al. Complications of harvesting
a connective tissue graft from the palate. A retrospective study and description of a new technique. J ClinExp Dent 2017;9(12):e1439-e1445. Read on Pubmed
2. Griffin TJ, Cheung WS, Zavras AI, et al.
Postoperative complications following gingival
augmentation procedures. J Periodontol
2006;77(12):2070-2079. Read on Pubmed
3. Harris RJ, Miller R, Miller LH, et al. Complications
with surgical procedures utilizing connective
tissue grafts: a follow-up of 500 consecutively
treated cases. Int J Periodontics Restorative Dent
2005;25(5):449-459.C513 Read on Pubmed

6. Boekema B., Vlig F, Damink O.L. et al. Effect of poresize and cross-linking of a novel collagenelastin dermal
substitute on wound healing. J Mater Sci Mater Med
2014:25(2):423-433 Read on Pubmed7. Wessing B,
Vasilic N. Soft tissue augmentation with a new regenerative collagen 3-D matrix with oriented open pores
as a potential alternative to autologous connective
tissue grafts. Clin Oral Impl Res; 2014 Sep;25(s10)8. Sanz-Martin I, Encalada C, Sam-Sanchez I,
et al. Soft tissue augmentation at immediate
implants using a novel xenogeneic collagen matrix
in conjunction with immediate provisional restorations: A prospective case series. Clin Implant Dent
Relat Res 2019;21(1):145-153. Read on Pubmed
9. Cirillo F and Encalada C. Periodontal
plastic surgery: treatment of multiple gingival
recessions. FOR.org Read on FOR.org

creos™ xenofill
Basma, H. S., Saleh, M. H. A., Abou-Arraj, R. V.,
Imbrogno, M., Ravida, A., Wang, H. L., Li, P., & Geurs,N. (2023). Patient-reported outcomes of palatal
donor site healing using four different wound dressing
modalities following free epithelialized mucosal grafts:
A four-arm randomized controlled clinical trial. Journalof periodontology, 94(1), 88–97. Read on Pubmed

creos™ syntostitch
1. Abellán, D., Nart, J., Pascual, A., Cohen,
R. E., & Sanz-Moliner, J. D. (2016). Physicaland Mechanical Evaluation of Five Suture
Materials on Three Knot Configurations: An
in Vitro Study. Polymers, 8(4), 147. Read
Taysi AE, Ercal P, Sismanoglu S. Comparison between
tensile characteristics of various suture materials
with two suture techniques: an in vitro study. Clin
Oral Investig. 2021 Apr 14. Read on Pubmed
Silverstein LH, Kurtzman GM, Shatz PC. Suturing
for optimal soft-tissue management. J Oral
Implantol. 2009;35:82-90. Read on Pubmed

Silverstein LH. Suturing principles: Preserving needle
edges during dental suturing. PPAD. 2005;17:562-564.
Urban IA, Lozada JL, Wessing B, Suárez-López del Amo
F, Wang HL. Vertical Bone Grafting and Periosteal
Vertical Mattress Suture for the Fixation of Resorbable
Membranes and Stabilization of Particulate Grafts
in Horizontal Guided Bone Regeneration to Achieve
More Predictable Results: A Technical Report. Int
J Periodontics Restorative Dent. 2016;36(2):153159. doi:10.11607/prd.2627 Read on Pubmed

creos™ screw fixation
Plonka, A. B., Urban, I. A., & Wang, H. L. (2018).
Decision Tree for Vertical Ridge Augmentation. The
International journal of periodontics & restorative
dentistry, 38(2), 269–275. Read on Pubmed
Urban, I. A., Monje, A., Lozada, J., & Wang, H. L. (2017).
Principles for Vertical Ridge Augmentation in the
Atrophic Posterior Mandible: A Technical Review. The
International journal of periodontics & restorative
dentistry, 37(5), 639–645. Read on Pubmed
Gultekin, B. A., Cansiz, E., & Borahan, M. O. (2017).
Clinical and 3-Dimensional Radiographic Evaluationof Autogenous Iliac Block Bone Grafting and Guided
Bone Regeneration in Patients With Atrophic Maxilla.
Journal of oral and maxillofacial surgery : official
journal of the American Association of Oral andMaxillofacial Surgeons, 75(4), 709–722. https://doi.
org/10.1016/j.joms.2016.11.019 Read on Pubmed
Wessing B, Urban I, Montero E, et al. A multicenter
randomized controlled clinical trial using a newresorbable non-cross- linked collagen membrane
for guided bone regeneration at dehisced single
implant sites: interim results of a bone augmentation procedure. Clin Oral Impl Res;
2017;28(11):e218–e226. Read on Pubmed

35

Order online
Order our complete creos™
range 24 hours a day throughthe Nobel Biocare online store.
nobelbiocare.com/store

Order by phone
Call our customer service team orcontact your sales representative.
nobelbiocare.com/contact

nobelbiocare.com
GMT 90639 GB 2406 Printed in the EU © Nobel Biocare Services AG, 2024. All rights reserved. Distributed by: Nobel Biocare.
Disclaimer: Nobel Biocare, the Nobel Biocare logotype and all other trademarks are, if nothing else is stated or is evident from the context in a certain case,trademarks of Nobel Biocare. Please refer to nobelbiocare.com/trademarks for more information.
Product images are not necessarily to scale. All product images are for illustration purposes only and may not be an exact representation of the product.
Some products may not be regulatory cleared/released for sale in all markets. Please contact the local Nobel Biocare sales office for current product assortment
and availability. Caution: Federal (United States) law or the law in your jurisdiction may restrict this device to sale by or on the order of a dentist or a physician. See
Instructions For Use for full prescribing information, including indications, contraindications, warnings and precautions.
creos™ xenogain is manufactured for/by Nibec Co. Ltd., Chungcheongbuk-do, 27816 Korea and distributed by Nobel Biocare Services AG. creos™ xenoform is manufactured
for/by Chiyewon, Gyeonggido, Korea 11927and distributed by Nobel Biocare Services AG. creos™ syntogain is manufactured for/by Mimetis Biomaterials, Carrer deCartagena, 245, 3E, Barcelona 08025, Spain and distributed by Nobel Biocare Services AG. creos™ xenoprotect and creos™ mucogain are manufactured for/by Matricel
GmbH, Kaiserstrasse 100, 52134 Herzogenrath, Germany and distributed by Nobel Biocare Services AG. creos™ syntoprotect, creos™ syntostitch, creos™ screw fixation are
manufactured for/by Osteogenics Biomedical, 4620 71st St # 78, Lubbock, TX 79424, USA and distributed by Nobel Biocare Services AG. creos™ xenofill and creos™
xenofirm are manufactured for/by Collagen Matrix, Inc. 15 Thornton Road Oakland, NJ 07436 USA and distributed by Nobel Biocare Services AG.